



-continued


(11-31)




(11-33)



(13)




(14)



-continued

(18)



or a pharmaceutically acceptable salt or stereoisomer thereof.

12. (canceled)

17. A pharmaceutical composition, comprising a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17, which is in the form of a liquid for oral or parenteral administration.

19. (canceled)

20. A method of treating a disease or disorder mediated by dysregulated Pin1 activity, comprising administering a therapeutically effective amount of the compound or pharmaceutically acceptable salt or stereoisomer of claim 1.

21. The method of claim 20, wherein the disease is cancer, an autoimmune disease or a neurodegenerative disease.

22. The method of claim 21, wherein the cancer is characterized by:

the presence of cancer stem cells (CSCs);

the activation of at least one oncogene selected from the group consisting of: PML-RAR $\alpha$ , NF- $\kappa$ B,  $\beta$ -catenin, Notch1, Notch3, OCT4, MYC, MCL1, Cyclin D1, PKM2, JUN, PGK1, FOS, SF1, Tax, HER2, RAB2A, AKT, v53M, Nanog, STAT3, HIF1, HSF1, ER, RAF1, FOXM1, SEPT9, PIP, v-Rel, Survivin, PTP-PEST, AR, MYB, PLK, S6K, AIB1, FAK, NUR77, RSK2, MAP3K8, IRAK1, COX2 and HBx; or

the inactivation of at least one tumour suppressor selected from the group consisting of: PML, AMPK, FBXW7, TRF1, GRK2, SUV39H1, SMRT, RUNX3, RBBP8, ATR, RB1, SMAD, FOXO4, RAR $\alpha$ , BTK, CDK10, DAXX, KLF10, BAX and PIP4K.

23.-24. (canceled)

25. The method of claim 21 wherein the autoimmune disease is selected from the group consisting of lupus, asthma and arthritis.

26. The method of claim 21, wherein the neurodegenerative disease is Alzheimer's disease or Parkinson's disease.

27. (canceled)

\* \* \* \* \*